NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.358) was uploaded to the NHS England Website on Thursday 10, April 2025.
The following changes have been introduced:
Erdafitinib (ERD1)
Erdafitinib for unresectable locally advanced or metastatic urothelial carcinoma which has a susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alteration in patients previously treated with at least one line of therapy containing a PD-1 or PD-L1 inhibitor administered in the unresectable locally advanced or metastatic treatment setting where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Osimertinib in combination with pemetrexed and platinum- based chemotherapy (OSI4)
Osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first line treatment of adult patients with recurrent or locally advanced or metastatic non-small cell lung cancer exhibiting epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Lisocabtagene maraleucel (LIS01a)
Lisocabtagene maraleucel for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high grade B-cell lymphoma or primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B either in patients who relapsed within 12 months of completion of 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation or who are refractory to 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS1b) can only be completed as a continuation of this first part of the form (LIS1a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel
Treatment criterion (#12) updated
Pembrolizumab (PEMB6)
The treatment of relapsed or refractory classical Hodgkin lymphoma in CHILDREN who are stem cell transplant-ineligible and have failed brentuximab vedotin where the following criteria have been met
Treatment criterion (#14) updated